Co-founded in 2012 by PPD as majority owner and X-Chem, X-Rx is a biotech company with more than 80 years of combined drug discovery and development experience. The portfolio includes targets across a number of families with multiple series of chemical starting points.
X-Rx holds a collection of high value targets coupled with access to DNA-encoded libraries and strong competencies in structure-based drug design. X-Rx has the ability to quickly identify tractable lead series on a wide range of targets.
X-Rx has multiple leads at discovery phase in the following target areas: protein-protein interactions, epigenetics, kinases, ligases and GPCRs as well as access to new screens for novel targets.